Proportion of GPRD AF patients who met inclusion/exclusion criteria for RE-LY, ARISTOTLE and ROCKET-AF, stratified by risk of stroke and assessment method
| Patient population | Anticoagulant eligibility | GPRD AF patient population, N (%) | RE-LY GPRD AF patients meeting trial criteria, n (% (95% CI)) | ARISTOTLE GPRD AF patients meeting trial criteria n (% (95% CI)) | ROCKET-AF GPRD AF patients meeting trial criteria, n (% (95% CI)) |
|---|---|---|---|---|---|
| Total GPRD AF population | Not anticoagulant-eligible/potentially anticoagulant-eligible/should receive anticoagulant according to guidelines | 83 898 (100) | 53 640 (64 (63.59 to 64.41)) | 51 415 (61 (60.58 to 61.42)) | 39 892 (48 (47.66 to 48.34)) |
| Intermediate-risk or high-risk patients | |||||
| CHADS2 ≥1 | Potentially anticoagulant-eligible/should receive anticoagulant according to guidelines | 71 493 (85) | 52 783 (74 (73.68 to 74.32)) | 51 415 (72 (71.67 to 72.33)) | 39 892 (56 (55.64 to 56.36)) |
| CHA2DS2-VASc ≥1 | Potentially anticoagulant-eligible/should receive anticoagulant according to guidelines | 78 783 (94) | 53 640 (68 (67.67 to 68.33)) | 51 163 (65 (64.67 to 65.33)) | 39 892 (51 (50.65 to 51.35)) |
| High-risk patients | |||||
| CHADS2 ≥2 | Should receive anticoagulant according to guidelines | 49 099 (59) | 38 493 (78 (77.63 to 78.37)) | 35 712 (73 (72.61 to 73.39)) | 39 892 (81 (80.65 to 81.35)) |
| CHA2DS2-VASc ≥2 | Should receive anticoagulant according to guidelines | 72 824 (87) | 53 059 (73 (72.68 to 73.32)) | 50 623 (70 (69.67 to 70.33)) | 39 835 (55 (54.64 to 55.36)) |
AF, atrial fibrillation; GPRD, General Practice Research Database.